Patients already taking daily aspirin therapy should take 81 mg to 325 mg before PCI.301 304 (Level of Evidence: B) 2. Patients not on aspirin therapy should be given nonenteric aspirin 325 mg before PCI.301,303,304 (Level of Evidence: B) 3. After PCI, use of aspirin should be continued indef- initely.560 563 (Level of Evidence: A) 4. A loading dose of a P2Y12 receptor inhibitor should be given to patients undergoing PCI with stenting564 568 (Level of Evidence: A). Options include a. Clopidogrel 600 mg (ACS and non-ACS pa- tients)564 566 (Level of Evidence: B) b. Prasugrel 60 mg (ACS patients)567 (Level of Evi- dence: B) c. Ticagrelor 180 mg (ACS patients)568 (Level of Evidence: B) 5. The loading dose of clopidogrel for patients under- going PCI after fibrinolytic therapy should be 300 mg within 24 hours and 600 mg more than 24 hours after receiving fibrinolytic therapy.565,569 (Level of Evidence: C) 6. Patients should be counseled on the need for and risks of DAPT before placement of intracoronary stents, especially DES, and alternative therapies should be pursued if patients are unwilling or unable to comply with the recommended duration of DAPT.208 (Level of Evidence: C) 7. The duration of P2Y12 inhibitor therapy after stent implantation should generally be as follows: a. In patients receiving a stent (BMS or DES) dur- ing PCI for ACS, P2Y12 inhibitor therapy should be given for at least 12 months. Options include (Level of Evidence: B) b. 